Open Access

HOW I DO IT

How I Do It: Temporarily Implanted Nitinol Device (iTind)

Dean Elterman¹, Bruce Gao¹, Kevin C. Zorn², Naeem Bhojani², Bilal Chughtai³

1 Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
2 Division of Urology, Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
3 Department of Urology, Weill Cornell Medical College, New York, New York, USA
AddresscorrespondencetoDr.DeanEltermanMD,Division of Urology, Department of Surgery, University of Toronto, 399BathurstStreet,MP-8-317,Toronto,ONM5T2S8Canada

Canadian Journal of Urology 2021, 28(4), 10788-10793.

Abstract

Benignprostatichyperplasiaisacommonandprogressive diseaseaffectingagingmenwhichhasasignifcantimpact on quality of life. The second-generation Temporarily Implanted Nitinol Device (iTind) is an FDA approved temporaryprostaticurethraldevicewhichcanbedeployed using standard fexible cystoscopy without sedation or generalanesthesia.Thedeviceisleftin-situfor5to7days and is then entirely removed in the offce, using an open-ended silicone catheter. Prospective, randomized data indicate that iTind has favorable functional and sexual patient outcomes. Readers will familiarize themselves withiTind,signifcanthistoricalstudiesandthetechnique for deploying iTind using a fexible cystoscope in the offce setting.

---

Keywords

---